Jeanny B. Aragon-Ching, MD of the Inova Schar Cancer Institute has co-authored a groundbreaking bladder cancer research paper just published in the New England Journal of Medicine.
The large phase III clinical study showed that the addition of immunotherapy with Avelumab (Bavencio) increased the duration of overall survival by almost 50% in patients when given after chemotherapy in patients with locally advanced bladder cancer.
This practice-changing study showed how the addition of immunotherapy can have a dramatic impact on the lives of patients with certain cancers.
What is hsCRP, and how can it help predict your risk of developing heart disease?…
Recognition from U.S. News & World Report, Modern Healthcare and Press Ganey highlights Inova's commitment…
Raj Chand, MD, to serve as Interim President, Inova Loudoun Hospital Fairfax, VA — Inova is pleased to announce…
FDA-approved technology helps surgeons visualize ovarian cancer in real time during surgery FAIRFAX, Va. –…
Leesburg, VA — Inova Loudoun Hospital Mobile Health Services will be providing countywide blood pressure…
Study at a glanceInova’s incidental lung nodule program has shown a 76% reduction in time…